Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 16, Issue 10, 2013, Pages 2181-2194

  Meltzer, Herbert Y ^a   Rajagopal, Lakshmi ^a   Huang, Mei ^a   Oyamada, Yoshihiro ^a,b   Kwon, Sunoh ^a   Horiguchi, Masakuni ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotic; declarative memory; dopamine; GABA; glutamate; object recognition; phencyclidine; schizophrenia; serotonin

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; CLOZAPINE; DIZOCILPINE; F 15599; GLEMANSERIN; HALOPERIDOL; ILOPERIDONE; KETAMINE; LURASIDONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORCLOZAPINE; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; PIMAVANSERIN; QUETIAPINE; RISPERIDONE; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TANDOSPIRONE; UNCLASSIFIED DRUG; VOLINANSERIN; ZIPRASIDONE;

4 AMINOBUTYRIC ACID RELEASE; BRAIN REGION; COGNITIVE DEFECT; CONFERENCE PAPER; DECLARATIVE MEMORY; EXECUTIVE FUNCTION; HIPPOCAMPUS; HUMAN; INTERNEURON; LEARNING; LOCOMOTION; LONG TERM POTENTIATION; MEMORY; NONHUMAN; PERIRHINAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RETROSPLENIAL CORTEX; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84885664175     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000928     Document Type: Conference Paper

References (268)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2007) Sub-chronic psychotomimetic PCP induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21:198-205
2. Andrade R, Nicoll RA (1987) Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394:99-124
3. Arborelius L, Nokimos GG, Hacksell U, Svensson TH (1993) (R)-8-OHDPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148:465-466
4. Arvanov VL, Wang R (1998) MDL 100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates NMDA-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacol 18:197-209
5. Bado P, Madeira C, Vargas-Lopes C, Moulin TC, Wasilewska-Sampaio AP, Maretti L, de Oliveira RV, Amaral OB, Panizzutti R (2011) Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl) 218:461-470
6. Beneyto M, Lewis DA (2011) Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry. Int J Dev Neurosci 29:295-304. doi: 10.1016/j.ijdevneu.2010.08.003
7. Bennett MR (2011) Schizophrenia: Susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol 95:275-300
8. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028
9. Bortolozzi A, Masana M, Díaz-Mataix L, Cortés R, Scorza MC, Gingrich JA (2010) Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol 13(10):1299-1314
10. Boulay D et al. (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47-58
11. Broberg BV, Dias R, Glenthoj BY, Olsen CK (2008) Evaluation of neurodevelopmental model of schizophrenia-early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 190:160-163
12. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT (2007) The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psych 164:1593-1602
13. Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210-221
14. Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacol 15:442-455
15. Burnet PW, Eastwood SL, Harrison PJ (1997) [3H] WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565-574
16. Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI (2009) Subchronic effects of phencyclidine on dopamine and serotonin receptors: Implications for schizophrenia. J Mol Neurosci 38:227-235
17. Codony X, Vela JM, Ramírez MJ (2011) 5-HT(6) receptor and cognition. Curr Opin Pharmacol 11:94-100
18. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. Handb Exp Pharmacol 213:267-295
19. Dean B, Pavey G, Thomas D, Scarr E (2006) Cortical serotonin7, 1D and 1F receptors: Effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr Res 88:265-274
20. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action. J Neurosci 25:10831-10843
21. Dickinson D, Iannone VN,Wilk CM, Gold JM (2004) General and specific cognitive deficits in schizophrenia. Biol Psychiat 55:826-833
22. Dong C, Rovnaghi CR, Anand KJ (2012) Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells. Crit Care Med 40:2407-2216
23. Elsworth JD, Groman SM, Jentsch JD, Valles R, Shahid M, Wong E, Marston H, Roth RH (2012) Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacol 62:1442-1452
24. Ennaceur A, Delacour J (1988) A new one-Trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59
25. Faludi G, Mirnics K (2011) Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci 29:305-309
26. Fleischhacker WW, Simma AM (2012) Managing the prodrome of schizophrenia. Handb Exp Pharmacol 212:125-134
27. Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr., Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA (2013) Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacol 64:254-263
28. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, Tricklebank M (2012) NMDA receptors, cognition and schizophrenia-Testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacol 62:1401-1412
29. González-Blanch C, Crespo-Facorro B, Álvarez-Jiménez M, Rodríguez-Sánchez JM, Pelayo-Terán JM, Pérez-Iglesias R (2008) Pretreatment predictors of cognitive deficits in early psychosis. Psychol Med 28:737-746
30. Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition andfunctional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 72:41-51
31. Giovannini MG, Bartolini L, Kopf SR, Pepeu G (1998) Acetylcholine release from the frontal cortex during exploratory activity. Brain Res 784:218-227
32. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacol (Berl) 174:3-16
33. Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38
34. Guzmán-Ramos K, Moreno-Castilla P, Castro-Cruz M, McGaugh JL, Martínez-Coria H, Laferla FM, Bermúdez-Rattoni F (2012) Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learn Mem 19:453-460
35. Hagger C, Buckley P, Kenny JT (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712
36. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18:448-454
37. Harich S, Koch M, Schwabe K (2007) Effects of repeated dizocilpine treatment on adult rat behaviour after neonatal lesions of the entorhinal cortex. Prog Neuropsychopharcol Biol Psych 32:816-827
38. Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiat 158:176-184
39. Hashimoto K, Fujita Y, Iyo M (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of Fluoxamine: Role of sigma-1 receptors. Neuropsychopharmacol 32:514-521
40. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991) Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48(4):355-363
41. Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM, Schacter DL (2000) Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psych 48:651-657
42. Hedlund PB (2009) The 5-HT7 receptor and disorders of the nervous system: An overview. Psychopharmacol 206:345-354
43. Hori T, Abe S, Baba A, Suzuki T, Shiraishi H (2000) Effects of repeated phencyclidine treatment on serotonin transporter in rat brain. Neurosci Lett 280:53-56
44. Horiguchi M, Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)induced novel object recognition (NOR) deficit in rats. Psychopharmacol (Berl) 221:205-215
45. Horiguchi M, Meltzer HY (2013) Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism. Behav Brain Res 247:158-164
46. Horiguchi M, Hannaway KE, Adelekun AE, Huang M, Jayathilake K, Meltzer HY (2011a) D(1) receptor agonists reverse the sub-chronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. Behav Brain Res 238:36-43
47. Horiguchi M, Huang M, Meltzer HY (2011b) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605-614
48. Horiguchi M, Huang M, Meltzer HY (2011c) Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in sub-chronic phencyclidine-Treated rats. Psychopharmacol (Berl) 217:13-24
49. Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-Administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacol 37:2175-2183
50. Hotte M, Naudon L, Jay TM (2005) Modulation of recognition and temporal order memory retrieval by dopamine D1 receptor in rats. Neurobiol Learn Mem 84:85-92
51. Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY (2008) Asenapine increases dopamine, norepinephrine, andacetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacol 33(12):2934-2945
52. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436-440
53. Ibrahim HM, Tamminga CA (2012) Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol 13:1587-1594
54. Ichikawa J, Meltzer HY (1999) R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232
55. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
56. Ichikawa J, Dai J, Meltzer HY (2002c) 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42
57. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: Involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacol 208:23-36
58. Ihalainen J, Sarajärvi T, Kemppainen S, Keski-Rahkonen P, Lehtonen M, Tanila H (2010) A novel delayed non-match to sample object recognition task that allows simultaneous in vivo microdialysis. J Neurosci Methods 189:210-215
59. Jenkins TA, Elliott JJ, Ardis TC, Cahir M, Reynolds GP, Bell R, Cooper SJ (2010) Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. Behav Brain Res 208:479-483
60. Jones AK, Srivastava PD, Allen AJ, Strachan TR, Roth LB, Penzes P (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA 106:19575-19580
61. Kalkstein S, Hurford I, Gur RC (2010) Neurocognition in schizophrenia. Curr Top Behav Neurosci 4:373-390
62. Kantrowitz JT, Javitt DC (2010) Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 4:189-200
63. Karasawa J, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78-83
64. Kawabe K, Miyamoto E (2008) Effects of neonatal repeated MK-801 treatment on delayed nonmatching-To-position responses in rats. Neuroreport 19:969-973
65. Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11-37
66. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiat 64:633-647
67. Kenny JT, Meltzer HY (1991) Attention and higher cortical functions in schizophrenia. J Neuropsychiat Clin Neurosci 3:269-275
68. Kim SH, Price MT, Olney JW, Farber NB (1999) Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-Adrenergic agonists. Mol Psych 4:344-352
69. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV (1994) Neuropsychological risk indicators for schizophrenia: A review of family studies. Schizophr Bull 20:103-119
70. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
71. Lejeune F, Millan MJ (1998) Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30:172-180
72. Li JT, Su YA, Guo CM, Feng Y, Yang Y, Huang RH, Si TM (2011) Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur J Pharmacol 652:65-72
73. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacol (Berl) 183:144-153
74. Lladó-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P (2012) 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex. Cereb Cortex 22:1487-1497
75. López-Gil X, Artigas F, Adell A (2010) Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: Relevance for antipsychotic action. Int J Neuropsychopharmacol 12:487-499
76. Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recognition and its relevance to schizophrenia: A review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacol (Berl) 220:647-672
77. McLean SL, Idris NF, Woolley ML, Neill JC (2009a) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440-450
78. McLean SL, Woolley ML, Thomas D, Neill JC (2009b) Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacol (Berl) 206:403-414
79. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
80. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197
81. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
82. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
83. Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models ofacetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacol 33(12):2934-2945
84. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436-440
85. Ibrahim HM, Tamminga CA (2012) Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol 13:1587-1594
86. Ichikawa J, Meltzer HY (1999) R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232
87. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
88. Ichikawa J, Dai J, Meltzer HY (2002c) 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42
89. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: Involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacol 208:23-36
90. Ihalainen J, Sarajärvi T, Kemppainen S, Keski-Rahkonen P, Lehtonen M, Tanila H (2010) A novel delayed non-match to sample object recognition task that allows simultaneous in vivo microdialysis. J Neurosci Methods 189:210-215
91. Jenkins TA, Elliott JJ, Ardis TC, Cahir M, Reynolds GP, Bell R, Cooper SJ (2010) Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. Behav Brain Res 208:479-483
92. Jones AK, Srivastava PD, Allen AJ, Strachan TR, Roth LB, Penzes P (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA 106:19575-19580
93. Kalkstein S, Hurford I, Gur RC (2010) Neurocognition in schizophrenia. Curr Top Behav Neurosci 4:373-390
94. Kantrowitz JT, Javitt DC (2010) Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 4:189-200
95. Karasawa J, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78-83
96. Kawabe K, Miyamoto E (2008) Effects of neonatal repeated MK-801 treatment on delayed nonmatching-To-position responses in rats. Neuroreport 19:969-973
97. Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11-37
98. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiat 64:633-647
99. Kenny JT, Meltzer HY (1991) Attention and higher cortical functions in schizophrenia. J Neuropsychiat Clin Neurosci 3:269-275
100. Kim SH, Price MT, Olney JW, Farber NB (1999) Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-Adrenergic agonists. Mol Psych 4:344-352
101. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV (1994) Neuropsychological risk indicators for schizophrenia: A review of family studies. Schizophr Bull 20:103-119
102. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
103. Lejeune F, Millan MJ (1998) Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30:172-180
104. Li JT, Su YA, Guo CM, Feng Y, Yang Y, Huang RH, Si TM (2011) Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur J Pharmacol 652:65-72
105. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacol (Berl) 183:144-153
106. Lladó-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P (2012) 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex. Cereb Cortex 22:1487-1497
107. López-Gil X, Artigas F, Adell A (2010) Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: Relevance for antipsychotic action. Int J Neuropsychopharmacol 12:487-499
108. Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recognition and its relevance to schizophrenia: A review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacol (Berl) 220:647-672
109. McLean SL, Idris NF, Woolley ML, Neill JC (2009a) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440-450
110. McLean SL, Woolley ML, Thomas D, Neill JC (2009b) Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacol (Berl) 206:403-414
111. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
112. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197
113. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
114. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
115. Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models ofacetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacol 33(12):2934-2945
116. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436-440
117. Ibrahim HM, Tamminga CA (2012) Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol 13:1587-1594
118. Ichikawa J, Meltzer HY (1999) R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232
119. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
120. Ichikawa J, Dai J, Meltzer HY (2002c) 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42
121. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: Involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacol 208:23-36
122. Ihalainen J, Sarajärvi T, Kemppainen S, Keski-Rahkonen P, Lehtonen M, Tanila H (2010) A novel delayed non-match to sample object recognition task that allows simultaneous in vivo microdialysis. J Neurosci Methods 189:210-215
123. Jenkins TA, Elliott JJ, Ardis TC, Cahir M, Reynolds GP, Bell R, Cooper SJ (2010) Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. Behav Brain Res 208:479-483
124. Jones AK, Srivastava PD, Allen AJ, Strachan TR, Roth LB, Penzes P (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA 106:19575-19580
125. Kalkstein S, Hurford I, Gur RC (2010) Neurocognition in schizophrenia. Curr Top Behav Neurosci 4:373-390
126. Kantrowitz JT, Javitt DC (2010) Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 4:189-200
127. Karasawa J, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78-83
128. Kawabe K, Miyamoto E (2008) Effects of neonatal repeated MK-801 treatment on delayed nonmatching-To-position responses in rats. Neuroreport 19:969-973
129. Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11-37
130. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiat 64:633-647
131. Kenny JT, Meltzer HY (1991) Attention and higher cortical functions in schizophrenia. J Neuropsychiat Clin Neurosci 3:269-275
132. Kim SH, Price MT, Olney JW, Farber NB (1999) Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-Adrenergic agonists. Mol Psych 4:344-352
133. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV (1994) Neuropsychological risk indicators for schizophrenia: A review of family studies. Schizophr Bull 20:103-119
134. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
135. Lejeune F, Millan MJ (1998) Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30:172-180
136. Li JT, Su YA, Guo CM, Feng Y, Yang Y, Huang RH, Si TM (2011) Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur J Pharmacol 652:65-72
137. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacol (Berl) 183:144-153
138. Lladó-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P (2012) 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex. Cereb Cortex 22:1487-1497
139. López-Gil X, Artigas F, Adell A (2010) Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: Relevance for antipsychotic action. Int J Neuropsychopharmacol 12:487-499
140. Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recognition and its relevance to schizophrenia: A review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacol (Berl) 220:647-672
141. McLean SL, Idris NF, Woolley ML, Neill JC (2009a) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440-450
142. McLean SL, Woolley ML, Thomas D, Neill JC (2009b) Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacol (Berl) 206:403-414
143. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
144. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197
145. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
146. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
147. Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models ofpsychosis and cognitive impairment. Psychopharmacol (Berl) 213:289-305
148. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012a) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day. Schizophrenia Res 141:144-152
149. Meltzer HY, Massey BW, Horiguchi M (2012b) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572-1586
150. Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125
151. Meneses A (2007) Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short-And long-Term memory. Behav Brain Res 184:81-90
152. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T (1988) Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents. Biochem Pharmacol 37:3277-3283
153. Nabeshima T, Mouri A, Murai R, Noda Y (2006) Animal model of schizophrenia: Dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci 1086:160-168
154. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacol (Berl) 202:315-328
155. Nagai T, Ibi D, Yamada K (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biol Pharm Bull 34(9):1364-1368
156. Nakatani-Pawlak A, Yamaguchi K, Tatsumi Y, Mizoguchi H, Yoneda Y (2009) Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull 32:1576-1583
157. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative
158. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacol 20:106-118
159. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256
160. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, Nuechterlein KH, Green MF, Cannon TD (2006) Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res 84:100-111
161. Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S (1993) Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264:158-165
162. Pessia M, Jiang ZG, North RA, Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654:324-330
163. Phillips AG, Ahn S, Floresco SB (2004) Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci 24:547-553
164. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacol 32:17-34
165. Piper M, Beneyto M, Burne TH, Eyles DW, Lewis DA, McGrath JJ (2012) The neurodevelopmental hypothesis of schizophrenia: Convergent clues from epidemiology and neuropathology. Psychiat Clin North Am 35:571-584
166. Powell SB (2010) Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Bahav Neurosci 4:435-481
167. Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, Bobo WV, Brennan MD (2011) Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12:471-480
168. Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994) 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18(3):218-224
169. Roberts AJ, Hedlund PB (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22:762-771
170. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr., Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
171. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624
172. Scharfetter J (2001) Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2(3):251-261
173. Schwabe K, Klein S, Koch M (2006) Behavioral effects of neonatal lesions of the medial prefrontal cortex and sub-chronic pubertal treatment with phencyclidine of adult rats. Behav Brain Res 168:150-160
174. Sehatpour P, Dias EC, Butler PD, Revheim N, Guilfoyle DN, Foxe JJ, Javitt DC (2010) Impaired visual object processing across an occipital-frontal- hippocampal brain network in schizophrenia: An integrated neuroimaging study. Arch Gen Psych 67:772-782
175. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73
176. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435-1439
177. Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behav Brain Res 191:26-31
178. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-inducedpsychosis and cognitive impairment. Psychopharmacol (Berl) 213:289-305
179. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012a) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day. Schizophrenia Res 141:144-152
180. Meltzer HY, Massey BW, Horiguchi M (2012b) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572-1586
181. Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125
182. Meneses A (2007) Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short-And long-Term memory. Behav Brain Res 184:81-90
183. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T (1988) Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents. Biochem Pharmacol 37:3277-3283
184. Nabeshima T, Mouri A, Murai R, Noda Y (2006) Animal model of schizophrenia: Dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci 1086:160-168
185. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacol (Berl) 202:315-328
186. Nagai T, Ibi D, Yamada K (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biol Pharm Bull 34(9):1364-1368
187. Nakatani-Pawlak A, Yamaguchi K, Tatsumi Y, Mizoguchi H, Yoneda Y (2009) Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull 32:1576-1583
188. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432
189. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacol 20:106-118
190. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256
191. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, Nuechterlein KH, Green MF, Cannon TD (2006) Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res 84:100-111
192. Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S (1993) Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264:158-165
193. Pessia M, Jiang ZG, North RA, Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654:324-330
194. Phillips AG, Ahn S, Floresco SB (2004) Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci 24:547-553
195. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacol 32:17-34
196. Piper M, Beneyto M, Burne TH, Eyles DW, Lewis DA, McGrath JJ (2012) The neurodevelopmental hypothesis of schizophrenia: Convergent clues from epidemiology and neuropathology. Psychiat Clin North Am 35:571-584
197. Powell SB (2010) Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Bahav Neurosci 4:435-481
198. Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, Bobo WV, Brennan MD (2011) Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12:471-480
199. Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994) 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18(3):218-224
200. Roberts AJ, Hedlund PB (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22:762-771
201. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr., Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
202. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624
203. Scharfetter J (2001) Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2(3):251-261
204. Schwabe K, Klein S, Koch M (2006) Behavioral effects of neonatal lesions of the medial prefrontal cortex and sub-chronic pubertal treatment with phencyclidine of adult rats. Behav Brain Res 168:150-160
205. Sehatpour P, Dias EC, Butler PD, Revheim N, Guilfoyle DN, Foxe JJ, Javitt DC (2010) Impaired visual object processing across an occipital-frontal- hippocampal brain network in schizophrenia: An integrated neuroimaging study. Arch Gen Psych 67:772-782
206. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73
207. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435-1439
208. Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behav Brain Res 191:26-31
209. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-inducedpsychosis and cognitive impairment. Psychopharmacol (Berl) 213:289-305
210. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012a) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day. Schizophrenia Res 141:144-152
211. Meltzer HY, Massey BW, Horiguchi M (2012b) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572-1586
212. Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125
213. Meneses A (2007) Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short-And long-Term memory. Behav Brain Res 184:81-90
214. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T (1988) Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents. Biochem Pharmacol 37:3277-3283
215. Nabeshima T, Mouri A, Murai R, Noda Y (2006) Animal model of schizophrenia: Dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci 1086:160-168
216. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacol (Berl) 202:315-328
217. Nagai T, Ibi D, Yamada K (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biol Pharm Bull 34(9):1364-1368
218. Nakatani-Pawlak A, Yamaguchi K, Tatsumi Y, Mizoguchi H, Yoneda Y (2009) Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull 32:1576-1583
219. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432
220. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacol 20:106-118
221. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256
222. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, Nuechterlein KH, Green MF, Cannon TD (2006) Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res 84:100-111
223. Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S (1993) Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264:158-165
224. Pessia M, Jiang ZG, North RA, Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654:324-330
225. Phillips AG, Ahn S, Floresco SB (2004) Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci 24:547-553
226. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacol 32:17-34
227. Piper M, Beneyto M, Burne TH, Eyles DW, Lewis DA, McGrath JJ (2012) The neurodevelopmental hypothesis of schizophrenia: Convergent clues from epidemiology and neuropathology. Psychiat Clin North Am 35:571-584
228. Powell SB (2010) Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Bahav Neurosci 4:435-481
229. Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, Bobo WV, Brennan MD (2011) Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12:471-480
230. Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994) 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18(3):218-224
231. Roberts AJ, Hedlund PB (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22:762-771
232. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr., Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
233. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624
234. Scharfetter J (2001) Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2(3):251-261
235. Schwabe K, Klein S, Koch M (2006) Behavioral effects of neonatal lesions of the medial prefrontal cortex and sub-chronic pubertal treatment with phencyclidine of adult rats. Behav Brain Res 168:150-160
236. Sehatpour P, Dias EC, Butler PD, Revheim N, Guilfoyle DN, Foxe JJ, Javitt DC (2010) Impaired visual object processing across an occipital-frontal- hippocampal brain network in schizophrenia: An integrated neuroimaging study. Arch Gen Psych 67:772-782
237. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73
238. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435-1439
239. Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behav Brain Res 191:26-31
240. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-inducedobject recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332:622-631
241. Snigdha S, Idris N, Grayson B, Shahid M, Neill JC (2011) Asenapine improves phencyclidine-induced object recognition deficits in the rat: Evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacol (Berl) 214:843-853
242. Song I, Savtchenko L, Semyanov A (2011) Tonic excitation or inhibition is set by GABA(A) conductance in hippocampal interneurons. Nat Commun 2:376
243. Stanley EM, Wilson MA, Fadel JR (2012) Hippocampal neurotransmitter efflux during one-Trial novel object recognition in rats. Neurosci Lett 511:38-42
244. Steward LJ, Kennedy MD, Morris BJ, Pratt JA (2004) The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors. Neuropharmacol 47:527-537
245. Stone WA, Hsi X (2011) Declarative memory deficits and schizophrenia: Problems and prospects. Neurobiol Learn Mem 96(4):544-552
246. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996) Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708(1-2):209-214
247. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia (letter). J Clin Psychopharmacol 20:386-388
248. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001a) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868
249. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001b) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725
250. Tajiri M, Hayata-Takano A, Seiriki K, Ogata K, Hazama K, Shintani N, Baba A, Hashimoto H (2012) Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: Therapeutic implications for psychiatric disorders. J Mol Neurosci 48:473-481
251. Tanaka H, Tatsuno T, Shimizu H, Hirose A, Kumasaka Y, Nakamura M (1995) Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen Pharmacol 26:1765-1772
252. Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vige X, Biton B, Steinberg R, Francon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrie P, Scatton B (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacol 30:1963-1985
253. Thomases DR, Cass DK, Tseng KY (2013) Periadolescent exposure to the NMDA receptor antagonist MK-801 impairs the functional maturation of local GABAergic circuits in the adult prefrontal cortex. J Neurosci 33:26-34
254. Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD (2009) Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacol 56:1001
255. To Z, Bonhaus DW, Eglen RM (1995) Characterization and distribution of putative 5-HT7 receptors in guinea pig brain. Br J Pharmacol 115:107-116
256. Tokarski K, Kusek M, Hess G (2011) 5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area. J Physiol Pharmacol 62:535-540
257. Ullman MT (2001) The declarative/procedural model of lexicon and grammar. J Psycholinguist Res 30:37-69
258. Waddington JL, Lane A, Scully PJ, Larkin C, O'Callaghan E (1998) Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease? Psychiatr Clin North Am 21:123-149
259. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn KU (2005) Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: Randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol 30:381-390
260. Wang CZ, Johnson KM (2005) Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J NeuroSci Res 81:284-292
261. Watanabe M, Kodama T, Hikosaka K (1997) Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol 78:2795-2798
262. Wedzony K, Mackowiak M, Fija K, Golembiowska K (1996) Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur J Pharmacol 305:73-78
263. Wesolowska A, Kowalska M (2008) Influence of serotonin 5-HT (7) receptor blockade on the behavioral and neurochemical effects of imipramine in rats. Pharmacol Rep 60:464-474
264. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-Analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472
265. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202
266. Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z (2005) Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci 25:5488-5501
267. Yuen EY, Jiang Q, Chen P, Feng J, Yan Z (2008) Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of N-methyl-D-Aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283:17194-17204
268. Yuen EY, Li X,Wei J, Horiguchi M, Meltzer HY, Yan Z (2012) The novel antipsychotic drug lurasidone enhances N-methyl-D-Aspartate receptor-mediated synaptic responses. Mol Pharmacol 81:113-119